Diabetes significantly compounds cardiovascular risk following coronary stenting, regardless of peripheral arterial disease status. This study was presented at the European Society of Cardiology Congress 2025. 

Patient-level data from 9,204 all-comer participants across four randomized trials were analyzed to evaluate three-year outcomes after percutaneous coronary intervention with new-generation drug-eluting stents. Among 695 patients with peripheral arterial disease, 208 had diabetes, while 1,539 of 8,454 patients without peripheral arterial disease had diabetes. 

Across both groups, diabetes was associated with older age, higher body mass index, and greater prevalence of hypertension. At three years, major adverse cardiac events occurred more frequently in patients with diabetes than in those without, with hazard ratios of 1.56 and 1.83 in patients with and without peripheral arterial disease, respectively.

These findings underscore that diabetes is a profound, independent risk factor for adverse outcomes after stenting, reinforcing the need for vigilant risk management in this high-risk population.